Actinium Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Actinium Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 67.7% bzw. 58.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 67.5% pro Jahr wachsen soll.

Wichtige Informationen

67.7%

Wachstumsrate der Gewinne

67.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.1%
Wachstumsrate der Einnahmen	58.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:ATNM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	130	40	-9	-11	6
12/31/2025	57	-15	-43	-47	7
12/31/2024	N/A	-47	-52	-47	6
3/31/2024	0	-46	-40	-40	N/A
12/31/2023	0	-49	-47	-47	N/A
9/30/2023	N/A	-50	-48	-48	N/A
6/30/2023	0	-46	-42	-42	N/A
3/31/2023	0	-39	-1	-1	N/A
12/31/2022	1	-33	8	9	N/A
9/30/2022	1	-30	11	11	N/A
6/30/2022	1	-27	11	11	N/A
3/31/2022	1	-25	-21	-21	N/A
12/31/2021	1	-25	-21	-21	N/A
9/30/2021	1	-23	-22	-22	N/A
6/30/2021	1	-22	-22	-21	N/A
3/31/2021	1	-22	-22	-21	N/A
12/31/2020	N/A	-22	-22	-22	N/A
9/30/2020	N/A	-20	-20	-20	N/A
6/30/2020	N/A	-21	-21	-21	N/A
3/31/2020	N/A	-22	-22	-22	N/A
12/31/2019	N/A	-22	-22	-21	N/A
9/30/2019	N/A	-24	-21	-21	N/A
6/30/2019	N/A	-23	-22	-22	N/A
3/31/2019	N/A	-23	-21	-21	N/A
12/31/2018	N/A	-24	-21	-21	N/A
9/30/2018	N/A	-22	-20	-19	N/A
6/30/2018	N/A	-23	-19	-19	N/A
3/31/2018	N/A	-25	-22	-22	N/A
12/31/2017	N/A	-27	N/A	-22	N/A
9/30/2017	N/A	-28	N/A	-23	N/A
6/30/2017	N/A	-28	N/A	-22	N/A
3/31/2017	N/A	-28	N/A	-21	N/A
12/31/2016	N/A	-24	N/A	-21	N/A
9/30/2016	N/A	-24	N/A	-21	N/A
6/30/2016	N/A	-22	N/A	-18	N/A
3/31/2016	N/A	-22	N/A	-17	N/A
12/31/2015	N/A	-21	N/A	-19	N/A
9/30/2015	N/A	-20	N/A	-20	N/A
6/30/2015	N/A	-22	N/A	-20	N/A
3/31/2015	N/A	-11	N/A	-18	N/A
12/31/2014	N/A	-25	N/A	-14	N/A
9/30/2014	N/A	-25	N/A	-11	N/A
6/30/2014	N/A	-20	N/A	-8	N/A
3/31/2014	N/A	-27	N/A	-6	N/A
12/31/2013	N/A	-11	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ATNM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ATNM wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ATNM wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ATNMDie Einnahmen des Unternehmens (58.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ATNMDie Einnahmen des Unternehmens (58.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ATNM in 3 Jahren voraussichtlich hoch sein wird

Actinium Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date pushed back to 2026

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Price target decreased by 13% to US$24.78

Recent updates

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

Consensus forecasts updated

Price target decreased to US$35.00

Actinium Pharmaceuticals, Inc. Announces Safety Data from Phase 3 SIERRA Trial of Iomab-B

Actinium Pharmaceuticals, Inc. Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

New 90-day low: US$7.75

Actinium Pharmaceuticals, Inc. Appoints Mark Kubik as Chief Business Officer

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA Trial

New 90-day low: US$8.08

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH

Actinium Pharmaceuticals, Inc. Appoints Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs

New 90-day high: US$12.01

Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML